### Gemcitabine

**Indication**: Other specified malignant neoplasms of bronchus or lung  
**ICD11 code**: 2C75.Y

**INN**: Gemcitabine  
**Medicine type**: Chemical agent  
**List type**: Complementary  
**Formulations**: Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection  
**EML status history**: First added in 2015 (TRS 994)  
**Sex**: All  
**Age**: Adolescents and adults  
**Therapeutic alternatives**: The recommendation is for this specific medicine  
**Patent information**: Patents have expired in most jurisdictions  
**Tags**: Cancer

**Wikipedia**: Gemcitabine  
**DrugBank**: Gemcitabine

### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, gemcitabine was added to the complementary list of the EML for use in treatment protocols for non-small cell lung cancer. The relevant extract from TRS994 regarding the Expert Committee’s consideration of treatment protocols for non-small cell lung cancer is attached.